The Russian remote patient monitoring industry is projected to grow at a high CAGR of 19.3% during the forecast period.
Global remote patient monitoring market would reach $2,130 million by 2022 from $703 million in 2015, growing at a CAGR of 17% from 2016 to 2022. Congestive heart failure segment is estimated to lead the market throughout the analysis period, closely followed by diabetes. Three-fourths of the remote patient monitoring market share was captured by North America and Europe in 2015.
Rising incidence of chronic diseases, and high-end technological advancements, have fueled the growth of the global remote patient monitoring market. On the other hand, unstable reimbursement regulations, and limited awareness about the technology have happened to curb the growth to some extent. However, growing developments in emerging markets have created a number of lucrative opportunities in the segment.
By condition the CHF segment accounted for the largest revenue in 2015 and is expected to dominate during the study period. On the other hand, the diabetes segment is anticipated to grow at the fastest CAGR throughout 2015-2022. By component, the devices segment will be both the highest revenue generating and fastest growing segment of the global remote patient monitoring (RPM) market. Based on geography, U.S. contributed to the largest share in 2015 and is projected to be dominant till 2022. Simultaneously, Saudi Arabia market is anticipated to grow at the fastest CAGR of 21.3% throughout the period.
Key findings of the Remote Patient Monitoring Market study:
- CHF was the leading segment in 2015, and is expected to maintain its lead throughout the analysis period.
- Diabetes will be the fastest growing segment throughout the analysis period.
- Devices will be both the highest revenue generating and fastest growing segment of the global remote patient monitoring (RPM) market.
- Saudi Arabia market for remote patient monitoring is projected to grow at a high CAGR of 21.3%.
- U.S. was the largest country market in 2015, and is projected to maintain its lead until 2022.
The key players profiled in the report include Boston Scientific Corporation, General Electric Company, Nihon Kohden Corporation, Johnson and Johnson and Omron Corporation Aerotel Medical Systems (1988) Ltd., Medtornic Plc, Masimo Corporation, Abbott Laboratories, and Biotronik SE & Co. KG. They have adopted a number of high-end strategies to retain a strong stand in the industry. The other players discussed in the value chain take in Jawbone, Microlife Corporation, SHL Telemedicine, Schiller AG, A&D Company Limited, Aipermon GmbH & Co. KG, Sorin Group, and Docobo Ltd.